Merck Publishes Science Paper on Scalable Oral PCSK9 Inhibitor Manufacturing
RAHWAY, N.J., May 7, 2026 Merck announced the publication of a landmark scientific paper in the journal Science detailing...
Merck
Advertisement
Merck Enpatoran Enters Phase 3 Trial for Lupus Treatment
Darmstadt, Germany | April 30, 2026 Merck has announced the first patient dosing in its global Phase 3 ELOWEN...
Merck Partners with Google Cloud for $1B AI Platform
Las Vegas, Nevada, USA – April 22, 2026 In a landmark move shaping the future of digital transformation in...
Merck FDA Approval of IDVYNSO HIV Treatment Drug
Rahway, New Jersey, USA – April 21, 2026 In a major breakthrough for HIV therapeutics, Merck has received U.S....
Merck ENFLONSIA Approved in EU for Infant RSV Protection
RAHWAY, N.J., April 17, 2026 Merck & Co., Inc. announced that the European Commission (EC) has approved ENFLONSIA™ (clesrovimab),...
Advertisements
Daiichi Sankyo Secures FDA Priority Review for ADC Therapy
Tokyo, Japan & Basking Ridge, New Jersey | April 13, 2026 Daiichi Sankyo, in collaboration with Merck & Co.,...
Merck Partners Infinimmune in $838M Antibody Discovery Deal
RAHWAY, N.J., USA — March 31, 2026 Merck & Co. has entered into a strategic antibody discovery collaboration with...
Merck to Acquire Terns to Strengthen CML Pipeline
RAHWAY, New Jersey & FOSTER CITY, California, March 25, 2026 Merck & Co. has announced a definitive agreement to...
Quotient Therapeutics, Merck Sign $2.2B IBD Deal
CAMBRIDGE, MASSACHUSETTS, March 24, 2026 Quotient Therapeutics has announced a multi-year research collaboration with Merck & Co. to discover...
Flare and Merck Partner to Advance FX-909 Combo in Cancer
CAMBRIDGE, MA – October 21, 2025 – Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company pioneering therapies that target...
Advertisement
